REVIEW article
Front. Pharmacol.
Sec. Cardiovascular and Smooth Muscle Pharmacology
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1626469
This article is part of the Research TopicNew Frontiers in Heart Failure Therapy: Mechanisms, Efficacy, and ChallengesView all 9 articles
Long-Acting Relaxin Analogues: a Novel Tool in Cardiology
Provisionally accepted
Łukasz Wołowiec*
Albert Jaśniak
Joanna OsiakDaria CzaplińskaAgata SzymczakJulia Anna Pęcherz Anna PęcherzGrzegorz Grześk- Department of Cardiology and Clinical Pharmacology, Faculty of Health Sciences, Nicolaus Copernicus University in Toruń, Bydgoszcz, Poland
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Serelaxin, a recombinant human relaxin, has emerged as a potential therapy for the future treatment of heart failure. However, its effectiveness has been limited by a short half-life and the need for intravenous administration. Recently developed long-acting relaxin analogues show promise in overcoming these limitations, as they exhibit an improved pharmacokinetic and pharmacodynamic profile while preserving the beneficial actions of relaxin.Their clinical utility has been confirmed in preclinical studies as well as in recently published first-in-human, randomized study focused on heart failure treatment(study ID: NCT04630067), and improvement of renal parameters in healthy volunteers (study ID NCT04768855). In this article, we provide an overview of the mechanisms underlying the effects of long-acting relaxin analogues and their positive impact on the cardiovascular system. Additionally, we present a comprehensive comparison between serelaxin and its novel analogues, exploring their potential implications for the future treatment of cardiovascular diseases.
Keywords: Serelaxin, Relaxin, Heart Failure, therapeutic, Pharmacology
Received: 10 May 2025; Accepted: 22 Jul 2025.
Copyright: © 2025 Wołowiec, Jaśniak, Osiak, Czaplińska, Szymczak, Pęcherz and Grześk. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Łukasz Wołowiec, Department of Cardiology and Clinical Pharmacology, Faculty of Health Sciences, Nicolaus Copernicus University in Toruń, Bydgoszcz, Poland
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.